tetano
Editor, Senior Moderator
Vaccine
. 2022 Aug 22;S0264-410X(22)01011-8.
doi: 10.1016/j.vaccine.2022.08.033. Online ahead of print.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Sitthichai Kanokudom[SUP] 1 [/SUP], Suvichada Assawakosri[SUP] 1 [/SUP], Nungruthai Suntronwong[SUP] 2 [/SUP], Jira Chansaenroj[SUP] 2 [/SUP], Chompoonut Auphimai[SUP] 2 [/SUP], Pornjarim Nilyanimit[SUP] 2 [/SUP], Preeyaporn Vichaiwattana[SUP] 2 [/SUP], Thanunrat Thongmee[SUP] 2 [/SUP], Ritthideach Yorsaeng[SUP] 2 [/SUP], Thaneeya Duangchinda[SUP] 3 [/SUP], Warangkana Chantima[SUP] 4 [/SUP], Pattarakul Pakchotanon[SUP] 3 [/SUP], Donchida Srimuan[SUP] 2 [/SUP], Thaksaporn Thatsanatorn[SUP] 2 [/SUP], Sirapa Klinfueng[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 5 [/SUP], Natthinee Sudhinaraset[SUP] 2 [/SUP], Nasamon Wanlapakorn[SUP] 2 [/SUP], Sittisak Honsawek[SUP] 6 [/SUP], Yong Poovorawan[SUP] 7 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 μg- than the 30 μg-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 μg- than the 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply.
Keywords: Booster; Clinical trial; Covid-19; Delta; Inactivated vaccine; Omicron; Reduced dose; Standard dose; Third dose; mRNA Vaccine.
. 2022 Aug 22;S0264-410X(22)01011-8.
doi: 10.1016/j.vaccine.2022.08.033. Online ahead of print.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Sitthichai Kanokudom[SUP] 1 [/SUP], Suvichada Assawakosri[SUP] 1 [/SUP], Nungruthai Suntronwong[SUP] 2 [/SUP], Jira Chansaenroj[SUP] 2 [/SUP], Chompoonut Auphimai[SUP] 2 [/SUP], Pornjarim Nilyanimit[SUP] 2 [/SUP], Preeyaporn Vichaiwattana[SUP] 2 [/SUP], Thanunrat Thongmee[SUP] 2 [/SUP], Ritthideach Yorsaeng[SUP] 2 [/SUP], Thaneeya Duangchinda[SUP] 3 [/SUP], Warangkana Chantima[SUP] 4 [/SUP], Pattarakul Pakchotanon[SUP] 3 [/SUP], Donchida Srimuan[SUP] 2 [/SUP], Thaksaporn Thatsanatorn[SUP] 2 [/SUP], Sirapa Klinfueng[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 5 [/SUP], Natthinee Sudhinaraset[SUP] 2 [/SUP], Nasamon Wanlapakorn[SUP] 2 [/SUP], Sittisak Honsawek[SUP] 6 [/SUP], Yong Poovorawan[SUP] 7 [/SUP]
Affiliations
- PMID: 36031500
- DOI: 10.1016/j.vaccine.2022.08.033
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 μg- than the 30 μg-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 μg- than the 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply.
Keywords: Booster; Clinical trial; Covid-19; Delta; Inactivated vaccine; Omicron; Reduced dose; Standard dose; Third dose; mRNA Vaccine.